ArticleEndocrine pathology1996
Localization of Epidermal Growth Factor (EGF) and Epidermal Growth Factor Receptor (EGFr) in Human Pituitary Adenomas and Nontumorous Pituitaries: An Immunocytochemical Study.
Article in Endocrine pathology, 1996. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 42 citations in OpenAlex.
- Trial
- Current and Emerging Medical Therapies in Pituitary Tumors.Journal of clinical medicine · 2022Review
- Ubiquitin-Specific Protease 8 Mutant Corticotrope Adenomas Present Unique Secretory and Molecular Features and Shed Light on the Role of Ubiquitylation on ACTH Processing.Neuroendocrinology · 2020Article
- Review
- Expression of EGFR in Pituitary Corticotroph Adenomas and Its Relationship With Tumor Behavior.Frontiers in endocrinology · 2019Article
- NK3R Mediates the EGF-Induced SLα Secretion and mRNA Expression in Grass Carp Pituitary.International journal of molecular sciences · 2018Article
- Pathogenesis of non-functioning pituitary adenomas.Pituitary · 2018Review
- Recent advances in understanding Cushing disease: resistance to glucocorticoid negative feedback and somatic USP8 mutations.F1000Research · 2017Review
- Genetics of Cushing's disease: an update.Journal of endocrinological investigation · 2016Review
- USP8: a novel therapeutic target for Cushing's disease.Endocrine · 2015Review
- ErbB receptor-driven prolactinomas respond to targeted lapatinib treatment in female transgenic mice.Endocrinology · 2015Article
- Molecular basis of pharmacological therapy in Cushing's disease.Endocrine · 2014Review
- Central role of the EGF receptor in neurometabolic aging.International journal of endocrinology · 2012Article
- Expression and function of ErbB receptors and ligands in the pituitary.Endocrine-related cancer · 2011Review
- HER2/ErbB2 receptor signaling in rat and human prolactinoma cells: strategy for targeted prolactinoma therapy.Molecular endocrinology (Baltimore, Md.) · 2011Article
- Heregulin regulates prolactinoma gene expression.Cancer research · 2009Article
- Rat prolactinoma cell growth regulation by epidermal growth factor receptor ligands.Cancer research · 2008Article
- Pituitary tumors: prognostic indicators.Endocrine · 2005Review
- Growth factors and cytokines in paragangliomas and pheochromocytomas, with special reference to sustentacular cells.Endocrine pathology · 2002Article
- Expression of Growth Factors in Normal and Neoplastic Pituitary Tissues.Endocrine pathology · 2000Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epidermal growth factor (EGF) and epidermal growth factor receptor (EGFr) were investigated by immunocytochemistry (ICH) in 57 human pituitary adenomas and 10 nontumorous autopsy pituitaries. EGF immunoreactivity was demonstrated in 24 adenomas (42%), representing 23 functioning tumors and 1 nonfunctioning tumor of oncocytic type, and in all nontumorous pituitaries. Among 40 tumors, EGFr was found positive in 15 functioning adenomas (37.5%), representing 50% of them. The presence of both EGF and EGFr was found mainly in corticotroph adenomas (60%) and less frequently in somatotroph and lactotroph adenomas (20%). ICH on serial sections with EGF or EGFr and adrenocorticotrophic hormone (ACTH) or S-100 protein revealed that EGF and EGFr are localized specifically in corticotrophs and EGFr in stellate cells of nontumorous adenohypophysis. These results confirm the presence of EGF and EGFr in human pituitary adenomas and nontumorous pituitaries and highlight their frequent occurrence in hormone-producing adenomas. Further work is required to explore the possiblity that EGF and EGFr play a role in hormone production, release, and tumor progression.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.